Plaque Psoriasis

Novartis reported that 59% of patients at 24 weeks experienced little to no impact of their condition on their quality of life. Additionally, 87% of bio-naïve psoriasis patients remained on secukinumab through 12 months, indicating its tolerability in real-world settings.

The fixed-dose combination therapy from Valeant Pharmaceuticals International is vying to become the first and only approved topical lotion for the condition.

CIMZIA is the first Fc-free biologic of its kind for this patient population.

Taltz (ixekizumab) is the first FDA-approved treatment for moderate to severe plaque psoriasis that includes data on psoriasis in the genital area.

The therapy met all co-primary and ranked secondary endpoints in the 4 trials without displaying any new safety signals, according to AbbVie.

The therapy was approved on the evidence of a pivotal phase 3 clinical development program which tested the efficacy of the inhibitor versus placebo in 926 adult patients.

Patients taking ustekinumab showed a 19% improvement in aortic inflammation compared to placebo.

The label update for secukinumab (Cosentyx, Novartis) now includes the treatment for moderate-to-severe scalp psoriasis.

Nearly half of the study participants achieved complete skin at week 16, while 87% maintained the response at week 52.

The FDA has approved guselkumab for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Patients afflicted with psoriasis have higher odds of developing abdominal aortic aneurysms.

Researchers are closing in on a medical treatment for wart-like skin growths know as seborrheic keratosis.

Seniors who developed the painful rash commonly known as shingles may also be at higher risk of suffering a stroke or heart attack.

College kids who break out or get hives can, in fact, blame some of their skin problems on heightened levels of psychological stress.

Patients with plaque psoriasis often experience clear improvement in their skin conditions after undergoing tonsillectomy.

This 29-year-old man came in for a wellness evaluation but notes having had this rash for 8 years. Occasionally it itches, but otherwise is asymptomatic and he has had no treatment for it to date. He does not take any medications and has no significant past medical history.

A lot of work goes into a medication being approved for the public including many rounds of trials and adjustments along the way. For a new plaque psoriasis medication that work is well underway and the developers hope to have it to patients in the near future.

For more than 70 years methotrexate has been a popular tool in the prescription toolkit of doctors around the world. However, a recent case report by a team from the United Kingdom showed how important it is for prescribing doctors to also keep a close eye on some of the well-known adverse events associated with the medication.